JANONE INC (JAN)

Company Profile

JanOne, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. The company is headquartered in Las Vegas, Nevada and currently employs 199 full-time employees. The company went IPO on 2006-02-22. The firm is focused on identifying, acquiring, licensing, developing, partnering, and commercializing non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is an oral pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. The company operates in two segments: Biotechnology and Technology. Its biotechnology segment is focused on finding treatments for conditions that cause severe pain and to market drugs with non-addictive pain-relieving properties. Its recycling segment is an appliance recycling program, which offers recycling, replacement and additional services for utility energy efficiency programs and have established 20 Regional Processing Centers (RPCs) throughout the United States and Canada.

Company Info

JANONE INC

325 E Warm Springs Rd Ste 102

Las Vegas NEVADA 89119

P: 17029975968

CEO: Tony Isaac

Employees: 199

Website: https://janone.com/